HAVANA, June 19 (Reuters) – Cuba’s Soberana 2 vaccine candidate has shown 62% efficacy with just two of its three doses, state-run biopharmaceutical corporation BioCubaFarma said on Saturday, citing preliminary data from late phase trials.
Cuba, which has a decades-old reputed biotech sector, has five vaccine candidates in clinical trials, of which two – Soberana 2 and Abdala – are in late phase trials.
Reporting by Anett Rios
Writing by Sarah Marsh; Editing by David Gregorio
Our Standards: The Thomson Reuters Trust Principles.